| 词条 | MicroPort |
| 释义 |
| name = MicroPort Inc. | logo = MicroPort_Logo.png | type = Public | traded_as = {{hkex|853}} | industry = Medical Devices | foundation = 1998 | hq_location = Shanghai, China | key_people = Zhaohua Chang, CEO Glendy Wang, COO Martin Sun, CFO Qiyi Luo, CTO | products = | revenue = {{profit}} US$444.190 Million (2017 Annual)[1] | operating_income = {{profit}} US$318.397 Million (2017 Annual)[1] | net_income = {{profit}} US$51.209 Million (2017 Annual)[1] | num_employees = 5000 (2018) | homepage = {{url|www.microport.com}} }}MicroPort is a global medical device developer and manufacturer that is headquartered in Shanghai, China. It designs and produces products for a range of medical fields including cardiology, interventional radiology, orthopedics, electrophysiology, and surgical management.[2] MicroPort is considered to be among the top 100 medical device companies in 2018 and was selected to be the 2017 China Innovative Medical Device Company.[3][4] HistoryMicroPort was founded in 1998 by Zhaohua Chang, who currently serves as CEO, Chairman, and Director. The company rose to prominence from the early success of its coronary stent line due its focus on serving the needs of the Chinese device market.[5][6] It is now one of the top global manufacturers of cardiac interventional devices.[7] Notably, it produces the world's first and only commercially available targeted drug eluting stent system, which uses a significantly reduced amount of drug than traditional drug eluting stents while maintaining effectiveness.[8][9][10][11] As of early 2018, MicroPort is one of few medical device companies still developing a commercial coronary bioresorbable stent with ongoing clinical trials.[12][13][14] Beginning in the 2010s, MicroPort has rapidly expanded around the world via international acquisitions to other medical device industries, including orthopedics and cardiac rhythm management, and is valued at over US$1 Billion.[15][16] In 2019, MicroPort announced a US$498 Million investment to develop pacemakers and defibrillators in France.[17] AcquisitionsIn 2014 MicroPort expanded operations in the United States by acquiring Wright Medical's OrthoRecon business to become the 6th largest international producer of orthopedic devices.[18] MicroPort's orthopedic business is based in Arlington, Tennessee and in 2018 has expanded its business into India.[19] In 2018 MicroPort and LivaNova closed the sale of LivaNova's cardiac rhythm management business for $190M.[16] In 2018 MicroPort purchased Lombard Medical, a US-based endovascular device company, from bankruptcy after it defaulted on loans in early 2018.[20] References1. ^1 2 {{cite web|url=http://www.microport.com/en/attach/investor_pic/investors/announcements/eAnnouncement%20of%20Annual%20Results%20for%20the%20Year%20Ended%2031%20December%202017.pdf|title=MicroPort Annual Results for Year Ended 31 December 2017|publisher=MicroPort}} 2. ^{{cite web|url=http://www.microport.com/en/about.php?curr_page=company|title=About Us|website=MicroPort|publisher=MicroPort}} 3. ^{{cite|title=Top 100 Medical Device Companies|publisher=Greenlight Guru}} 4. ^{{cite web|url=https://www.marketscreener.com/MICROPORT-SCIENTIFIC-CORP-6727702/news/MicroPort-Scientific-Selected-as-2017-China-Innovative-Medical-Device-Co--25776640/|title=MicroPort Scientific : Æ Selected as "2017 China Innovative Medical Device Co|publisher=MarketScreener}} 5. ^{{cite web|url=https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapid=243756971|title=Company Overview of Shanghai MicroPort Medical (Group) Co., Ltd.|website=Bloomberg}} 6. ^{{cite web|url=https://www.scmp.com/news/china/society/article/2018263/solution-seeker-medical-device-developer-provides-international|title=Solution seeker: medical device developer provides international standards at lower price for Chinese patients|website=South China Morning Post}} 7. ^{{cite web|url=http://publicistreport.com/pharmaceuticals-and-healthcare/healthcare/global-cardiac-catheters-market-share-2018-microport.html|title=Global Cardiac Catheters Market Share 2018 Microport, Terumo, Cook and Lepu|website=Publicist Report}} 8. ^{{cite journal|last1=Lansky|first1=Alexandra|last2=Wijns|first2=William|last3=Xu|first3=Bo|last4=KelbÊk|first4=Henning|last5=van Royen|first5=Niels|last6=Zheng|first6=Ming|last7=Morel|first7=Marie-angËle|last8=Knaapen|first8=Paul|last9=Slagboom|first9=Ton|date=September 29, 2018|title=Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): a multicentre, open-label, randomised non-inferiority trial|url=https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31649-0/fulltext|journal=The Lancet|volume=392|issue=10153|pages=1117–1126|doi=10.1016/S0140-6736(18)31649-0|pmid=30190206|last10=Johnson|first10=Thomas W|last11=Vlachojannis|first11=Georgios|last12=Arkenbout|first12=Karin E|last13=Holmvang|first13=Lene|last14=Janssens|first14=Luc|last15=Ochala|first15=Andrez|last16=Brugaletta|first16=Salvatore|last17=Naber|first17=Christoph K|last18=Anderson|first18=Richard|last19=Rittger|first19=Harald|last20=Berti|first20=Sergio|last21=Barbato|first21=Emanuele|last22=Toth|first22=Gabor G|last23=Maillard|first23=Luc|last24=Valina|first24=Christian|last25=Buszman|first25=Pawel|last26=Thiele|first26=Holger|last27=Sch‰chinger|first27=Volker|last28=Baumbach|first28=Andreas}} 9. ^{{cite journal|last1=Gao|first1=RL|date=20 May 2013|title=A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial|journal=Eurointervention|volume=9|issue=1|pages=75ñ83|doi=10.4244/EIJV9I1A12|pmid=23685298}} 10. ^{{cite journal|last1=Xu|first1=B|last2=Gao|first2=RL|last3=Zhang|first3=RY|last4=Wang|first4=HC|last5=Li|first5=ZQ|last6=Yang|first6=YJ|last7=Ma|first7=CS|last8=Han|first8=YL|last9=Lansky|first9=AJ|date=March 2013|title=Efficacy and safety of FIREHAWKÆ abluminal groove filled biodegradable polymer sirolimus-eluting stents for the treatment of long coronary lesions: nine-month angiographic and one-year clinical results from TARGET I trial long cohort|journal=China Medical Journal|volume=126|issue=6|pages=1026ñ32|pmid=23506573|last10=Huo|first10=Y|last11=Li|first11=W|last12=Leon|first12=MB}} 11. ^{{cite web|url=https://www.youtube.com/watch?v=okhV50zMcwY|title=Round Table Expert - Firehawk Stent, proven fast healing from TARGET clinical program|publisher=EuroPCR}} 12. ^{{cite journal|last1=Regazzoli|first1=Damiano|last2=Leone|first2=Pier Pasquale|last3=Colombo|first3=Antonio|last4=Latib|first4=Azeem|date=9 August 2017|title=New generation bioresorbable scaffold technologies: an update on novel devices and clinical results|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583081/|journal=Journal of Thoracic Disease|volume=9|page=S979ñS985|doi=10.21037/jtd.2017.07.104}} 13. ^{{cite web|url=https://www.medscape.com/viewarticle/883696|title=Boston Scientific Halts Bioabsorbable-Scaffold Program|last1=Wendling|first1=Patrice|website=Medscape|publisher=WebMD}} 14. ^{{cite web|url=https://www.dicardiology.com/article/abbott-will-end-sales-absorb-bioresorbable-stent|title=Abbott Will End Sales of Absorb Bioresorbable Stent|last1=Fornell|first1=Dave|website=Diagnostic and Interventional Cardiology|publisher=Scranton Gillette Communications}} 15. ^{{cite web|url=https://ryortho.com/2014/06/surprising-microport-orthopedics/|title=Surprising MicroPort Orthopedics|website=Orthopedics This Week}} 16. ^1 {{cite web|url=https://www.massdevice.com/livanova-closes-190-crm-sale-to-microport/|title=LivaNova closes $190 CRM sale to MicroPort|website=Mass Device}} 17. ^{{cite web|url=https://www.washingtonpost.com/business/frances-macron-hosts-150-world-business-leaders/2019/01/21/51d669f6-1d6a-11e9-a759-2b8541bbbe20_story.html|title=French leader promotes foreign investment at Versailles|website=Washington Post}} 18. ^{{cite web|url=https://www.prnewswire.com/news-releases/microport-scientific-establishes-microport-orthopedics-through-acquisition-of-wright-medicals-orthorecon-business-239924311.html|title=MicroPort Scientific establishes MicroPort Orthopedics through acquisition of Wright Medical's OrthoRecon business|website=Cision PR Newswire}} 19. ^{{cite web|url=http://www.thehansindia.com/posts/index/Telangana/2018-02-23/MicroPort-forays-into-orthopaedic-implants-/361151|title=MicroPort forays into orthopaedic implants|website=The Hans India}} 20. ^{{cite web|url=https://www.prnewswire.com/news-releases/lombard-medical-operations-acquired-by-microport-scientific-corporation-in-a-restructuring-transaction-680914221.html|title=Lombard Medical Operations Acquired by MicroPort Scientific Corporation in a Restructuring Transaction|website=PR Newswire Association}} 11 : Medical device manufacturers|Implants (medicine)|Heart disease organizations|Life sciences industry|Manufacturing companies|Medical technology companies of China|Technology companies of China|Companies listed on the Hong Kong Stock Exchange|Manufacturing companies established in 1998|Technology companies established in 1998|Shanghai |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。